Infused Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Infused Drugs Market Report is Segmented by Drug (Small Molecules and Biologics), Therapeutic Area (Oncology, Gastrointestinal Diseases, Rheumatoid Arthritis, Immune Deficiencies, Cardiology, Neurology, Diabetes, and Other Therapeutic Areas), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value in USD for the Above Segments.

Infused Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Infused Drugs Market Size

Infused Drugs Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 9.12 Billion
Market Size (2030) USD 12.97 Billion
CAGR (2025 - 2030) 7.30 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Infused Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Infused Drugs Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Infused Drugs Market Analysis

The Infused Drugs Market size is estimated at USD 9.12 billion in 2025, and is expected to reach USD 12.97 billion by 2030, at a CAGR of 7.3% during the forecast period (2025-2030).

The key factors driving the growth of the infused drugs market are the growing prevalence of chronic diseases, advancements in drug delivery systems, and the rising geriatric population. For instance, in 2022, there were approximately 670 million people aged 60 years or older in Asia-Pacific, which accounted for roughly one in every seven people in the region. By 2050, the number is projected to be doubled to 1.3 billion. Among the elderly population in Asia, women comprise 54%, and this tends to increase with age due to their long life expectancy, according to a report by the United Nations Economic and Social Commission for Asia and the Pacific. The rising geriatric population is expected to drive the market over the forecast period.

  • Moreover, the increasing prevalence of chronic conditions such as cardiovascular diseases, oncology diseases, and diabetes contribute to the market's growth. For instance, according to the report published by the British Heart Foundation (BHF) in April 2023, more than 7.6 million people were living with heart and circulatory diseases in the United Kingdom in 2022, which is further projected to increase with the aging population, decreasing fertility rates, and increasing survivability from other chronic diseases. Hence, the rising prevalence of chronic diseases is expected to increase the demand for infused drugs to effectively manage these diseases, ultimately driving the market studied market.
  • Furthermore, increasing strategic activities such as acquisitions and product launches are also expected to drive the market. For instance, in March 2024, Bristol Myers Squibb received approval from the United States Food and Drug Administration for a biological product, Breyanzi, a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Breyanzi is delivered through a treatment process that culminates in a one-time infusion with a single dose containing CAR-positive viable T cells. Such product launches are expected to drive the market over the forecast period.
  • However, the side effects associated with infusion drugs, strict regulations, and the high cost of manufacturing and developing infusion drugs may restrict the growth of the infused drugs market.

Infused Drugs Industry Overview

The infused drugs market is moderately competitive. The key players are adopting various strategies such as product launches, expansion of the products and services into new regions, mergers, acquisitions, and entering new partnerships and collaborations to strengthen their position in the market. The key players include AstraZeneca, Sanofi SA, Teva Pharmaceutical Industries Ltd, Amgen, Inc., and Bristol-Myers Squibb Company.

Infused Drugs Market Leaders

  1. AstraZeneca

  2. Sanofi SA

  3. Bristol-Myers Squibb Company

  4. Amgen, Inc.

  5. Teva Pharmaceutical Industries Ltd.

  6. *Disclaimer: Major Players sorted in no particular order
Infused Drugs Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Infused Drugs Market News

  • September 2023: Eisai Co. Ltd and Biogen Inc. reported the approval of LEQEMBI intravenous infusion, a humanized anti-soluble aggregated amyloid beta monoclonal antibody in Japan. This approval signifies its recognition as a treatment to decelerate the progression of mild cognitive impairment and dementia resulting from Alzheimer’s Disease.
  • August 2023: Halozyme Therapeutics Inc. reported that the Medicines and Healthcare Products Regulatory Agency (MHRA) in Britain approved Roche’s Tecentriq SC using Halozyme’s Enhaze drug delivery technology. The Tecentriq SC, co-formulated with halozyme’s enzyme, enables subcutaneous delivery in about 7 minutes.

Infused Drugs Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in the Prevalence of Chronic Diseases
    • 4.2.2 Increasing Geriatric Population
  • 4.3 Market Restraints
    • 4.3.1 Side Effects Associated with the Medications
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Drug Type
    • 5.1.1 Small Molecules
    • 5.1.2 Biologics
  • 5.2 By Therapeutic Area
    • 5.2.1 Oncology
    • 5.2.2 Gastrointestinal Diseases
    • 5.2.3 Rheumatoid Arthritis
    • 5.2.4 Immune Deficiencies
    • 5.2.5 Cardiology
    • 5.2.6 Neurology
    • 5.2.7 Diabetes
    • 5.2.8 Other Therapeutic Areas
  • 5.3 By Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AstraZeneca
    • 6.1.2 Sanofi SA
    • 6.1.3 Pfizer Inc.
    • 6.1.4 Weefsel Pharma
    • 6.1.5 Parenteral Drugs (India) Limited
    • 6.1.6 Bristol-Myers Squibb Company
    • 6.1.7 Regeneron Pharmaceuticals Inc.
    • 6.1.8 Eisai Co. Ltd
    • 6.1.9 Amgen Inc.
    • 6.1.10 Teva Pharmaceutical Industries Ltd
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Infused Drugs Industry Segmentation

As per the scope of the report, IV infusion puts medicine, blood, or fluid directly into the bloodstream. This makes the treatment fast and powerful. The infused drugs market is segmented by drug, therapeutic area, and geography. By drug, the market is segmented into small molecules and biologics. In terms of therapeutic areas, the market is segmented into oncology, gastrointestinal diseases, rheumatoid arthritis, immune deficiencies, cardiology, neurology, diabetes, and other therapeutic areas. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers values in USD for the above segments.

By Drug Type Small Molecules
Biologics
By Therapeutic Area Oncology
Gastrointestinal Diseases
Rheumatoid Arthritis
Immune Deficiencies
Cardiology
Neurology
Diabetes
Other Therapeutic Areas
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Infused Drugs Market Research FAQs

How big is the Infused Drugs Market?

The Infused Drugs Market size is expected to reach USD 9.12 billion in 2025 and grow at a CAGR of 7.30% to reach USD 12.97 billion by 2030.

What is the current Infused Drugs Market size?

In 2025, the Infused Drugs Market size is expected to reach USD 9.12 billion.

Who are the key players in Infused Drugs Market?

AstraZeneca, Sanofi SA, Bristol-Myers Squibb Company, Amgen, Inc. and Teva Pharmaceutical Industries Ltd. are the major companies operating in the Infused Drugs Market.

Which is the fastest growing region in Infused Drugs Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Infused Drugs Market?

In 2025, the North America accounts for the largest market share in Infused Drugs Market.

What years does this Infused Drugs Market cover, and what was the market size in 2024?

In 2024, the Infused Drugs Market size was estimated at USD 8.45 billion. The report covers the Infused Drugs Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Infused Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Infused Drugs Industry Report

Statistics for the 2025 Infused Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Infused Drugs analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.